Brief: Biomea Fusion Says Icovamenib Data Show Muscle Preservation And Fat Reduction In Obesity And Diabetes
06/06/2026 24:37
BRIEF-Biomea Fusion Says Icovamenib Data Show Muscle Preservation And Fat Reduction In Obesity And Diabetes June 5 (Reuters) - Biomea Fusion Inc BMEA.O:
BIOMEA FUSION PRESENTS NEW CLINICAL AND TRANSLATIONAL DATA FOR ICOVAMENIB AT THE AMERICAN DIABETES ASSOCIATION (“ADA”) 86TH SCIENTIFIC SESSIONS AND ANNOUNCES EXPANSION OF ONGOING PHASE I BMF-650 STUDY
BIOMEA FUSION - ICOVAMENIB DATA SHOW MUSCLE PRESERVATION AND FAT REDUCTION IN OBESITY AND DIABETES
BIOMEA FUSION - ICOVAMENIB IMPROVES HBA1C AND C-PEPTIDE IN TYPE 1 DIABETES WITH NO IMMUNE ACTIVATION
BIOMEA FUSION: EXPANDED PHASE I BMF-650 STUDY TO EVALUATE A RAPID ONE-STEP TITRATION, ENHANCED WEIGHT LOSS POTENTIAL WITH ORAL GLP-1 RECEPTOR AGONIST
Source text: ID:nGNX63lwrN
Further company coverage: BMEA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biomea Fusion
See all newsUS RESEARCH ROUNDUP-BlackRock, Microsoft, TransDigm Group
Brief: Biomea Fusion Announces Phase 1 Results For Bmf-650, Its Investigational Next-Generation Oral Small Molecule Glp-1 Receptor Agonist
Brief: Biomea Fusion To Announce Phase I Results For Bmf-650, Its Next-Generation Oral Small-Molecule Glp-1 Receptor Agonist
Brief: Biomea Fusion Announces Termination Of Proposed Public Offering Of Securities
Brief: Biomea Fusion Announces Completion Of Enrollment In Covalent-211 Phase Ii Trial Of Icovamenib In Insulin-Deficient Type 2 Diabetes